Silence Therapeutics Plc Stock Price Prediction
| SLN Stock | USD 5.18 0.25 4.60% |
Momentum 43
Sell Extended
Oversold | Overbought |
EPS Estimate Next Quarter (0.26) | EPS Estimate Current Year (1.33) | EPS Estimate Next Year (0.90) | Wall Street Target Price 33.8 | EPS Estimate Current Quarter (0.23) |
Using Silence Therapeutics hype-based prediction, you can estimate the value of Silence Therapeutics PLC from the perspective of Silence Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Silence Therapeutics using Silence Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Silence using crowd psychology based on the activity and movement of Silence Therapeutics' stock price.
Silence Therapeutics Implied Volatility | 2.75 |
Silence Therapeutics' implied volatility exposes the market's sentiment of Silence Therapeutics PLC stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Silence Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Silence Therapeutics stock will not fluctuate a lot when Silence Therapeutics' options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Silence Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Silence because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Silence Therapeutics after-hype prediction price | USD 5.55 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Silence Therapeutics Basic Forecasting Models to cross-verify your projections. Silence Therapeutics After-Hype Price Density Analysis
As far as predicting the price of Silence Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Silence Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Silence Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Silence Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Silence Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Silence Therapeutics' historical news coverage. Silence Therapeutics' after-hype downside and upside margins for the prediction period are 1.53 and 9.57, respectively. We have considered Silence Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Silence Therapeutics is somewhat reliable at this time. Analysis and calculation of next after-hype price of Silence Therapeutics PLC is based on 3 months time horizon.
Silence Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Silence Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Silence Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Silence Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.39 | 4.02 | 0.12 | 0.10 | 6 Events / Month | 8 Events / Month | In about 6 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
5.18 | 5.55 | 2.21 |
|
Silence Therapeutics Hype Timeline
On the 27th of January Silence Therapeutics PLC is traded for 5.18. The entity has historical hype elasticity of 0.12, and average elasticity to hype of competition of -0.1. Silence is expected to increase in value after the next headline, with the price projected to jump to 5.55 or above. The average volatility of media hype impact on the company the price is over 100%. The price boost on the next news is projected to be 2.21%, whereas the daily expected return is at this time at -0.39%. The volatility of related hype on Silence Therapeutics is about 1634.15%, with the expected price after the next announcement by competition of 5.08. Silence Therapeutics PLC has 117 K in debt with debt to equity (D/E) ratio of 0.02, which may show that the company is not taking advantage of profits from borrowing. Considering the 90-day investment horizon the next expected press release will be in about 6 days. Check out Silence Therapeutics Basic Forecasting Models to cross-verify your projections.Silence Therapeutics Related Hype Analysis
Having access to credible news sources related to Silence Therapeutics' direct competition is more important than ever and may enhance your ability to predict Silence Therapeutics' future price movements. Getting to know how Silence Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Silence Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| CTNM | Contineum Therapeutics Class | 0.42 | 8 per month | 4.11 | 0.06 | 7.89 | (5.55) | 23.16 | |
| AMRN | Amarin PLC | 0.19 | 9 per month | 0.00 | (0.11) | 4.89 | (4.37) | 20.43 | |
| KYTX | Kyverna Therapeutics Common | (0.47) | 9 per month | 7.97 | 0.07 | 10.86 | (9.60) | 55.75 | |
| ALDX | Aldeyra | 0.23 | 7 per month | 4.47 | 0.00 | 6.27 | (8.84) | 42.93 | |
| CAPR | Capricor Therapeutics | (3.10) | 12 per month | 4.29 | 0.12 | 11.97 | (10.26) | 386.29 | |
| LXEO | Lexeo Therapeutics Common | (0.25) | 7 per month | 0.00 | (0.06) | 7.04 | (8.50) | 34.26 | |
| LYEL | Lyell Immunopharma | 0.24 | 9 per month | 4.04 | 0.11 | 12.12 | (7.92) | 31.14 | |
| MREO | Mereo BioPharma Group | 0.08 | 9 per month | 0.00 | (0.01) | 16.33 | (9.52) | 101.95 | |
| ANRO | Alto Neuroscience | (0.02) | 11 per month | 5.71 | 0.12 | 11.18 | (8.77) | 31.43 | |
| ACIU | AC Immune | 0.22 | 8 per month | 4.81 | 0.07 | 9.84 | (8.36) | 27.64 |
Silence Therapeutics Additional Predictive Modules
Most predictive techniques to examine Silence price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Silence using various technical indicators. When you analyze Silence charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Silence Therapeutics Predictive Indicators
The successful prediction of Silence Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Silence Therapeutics PLC, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Silence Therapeutics based on analysis of Silence Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Silence Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Silence Therapeutics's related companies. | 2023 | 2024 | 2025 | 2026 (projected) | Days Sales Outstanding | 344.89 | 227.04 | 204.34 | 194.12 | PTB Ratio | 7.68 | 0.79 | 0.71 | 0.68 |
Pair Trading with Silence Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Silence Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Silence Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Silence Stock
Moving against Silence Stock
| 0.83 | MARUF | Marubeni | PairCorr |
| 0.72 | HLN | Haleon plc Aggressive Push | PairCorr |
| 0.7 | VNDA | Vanda Pharmaceuticals | PairCorr |
| 0.62 | BFDE | Bedford Energy | PairCorr |
| 0.6 | CNOB | ConnectOne Bancorp Earnings Call This Week | PairCorr |
| 0.59 | DBVT | DBV Technologies | PairCorr |
The ability to find closely correlated positions to Silence Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Silence Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Silence Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Silence Therapeutics PLC to buy it.
The correlation of Silence Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Silence Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Silence Therapeutics PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Silence Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Silence Therapeutics Basic Forecasting Models to cross-verify your projections. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Silence Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.35) | Revenue Per Share | Quarterly Revenue Growth (0.89) | Return On Assets | Return On Equity |
The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Silence Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.